

Hans Wildiers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1912065/publications.pdf>

Version: 2024-02-01

237
papers

18,066
citations

23567

58
h-index

15732

125
g-index

250
all docs

250
docs citations

250
times ranked

19760
citing authors

#	ARTICLE	IF	CITATIONS
1	International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2595-2603.	1.6	1,380
2	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	27.8	1,099
3	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019, 104, 21-34.	6.2	711
4	Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. <i>Annals of Oncology</i> , 2015, 26, 288-300.	1.2	607
5	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. <i>Journal of the National Cancer Institute</i> , 2011, 103, 250-263.	6.3	596
6	Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 689-699.	10.7	595
7	Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). <i>Lancet Oncology</i> , The, 2012, 13, e148-e160.	10.7	505
8	MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2 ⁺ Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5218-5224.	7.0	492
9	Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 65, 156-163.	4.4	447
10	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	428
11	Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 743-754.	10.7	372
12	Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With a 2 HER2-Directed Regimens: Phase III NALA Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3138-3149.	1.6	355
13	Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 115-126.	10.7	333
14	A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. <i>Nature Medicine</i> , 2021, 27, 820-832.	30.7	330
15	Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. <i>Lancet Oncology</i> , The, 2007, 8, 1101-1115.	10.7	313
16	Performance of Two Geriatric Screening Tools in Older Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 19-26.	1.6	308
17	EORTC elderly task force position paper: Approach to the older cancer patient. <i>European Journal of Cancer</i> , 2010, 46, 1502-1513.	2.8	300
18	Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. <i>British Journal of Cancer</i> , 2003, 88, 1979-1986.	6.4	296

#	ARTICLE	IF	CITATIONS
19	Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study. <i>Annals of Oncology</i> , 2013, 24, 1306-1312.	1.2	285
20	End Points and Trial Design in Geriatric Oncology Research: A Joint European Organisation for Research and Treatment of Cancer "Alliance for Clinical Trials in Oncology" International Society of Geriatric Oncology Position Article. <i>Journal of Clinical Oncology</i> , 2013, 31, 3711-3718.	1.6	267
21	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	21.4	265
22	International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. <i>European Journal of Cancer</i> , 2007, 43, 14-34.	2.8	224
23	International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of Chemotherapy in Older Patients "An Analysis of the Medical Literature. <i>Journal of Clinical Oncology</i> , 2007, 25, 1832-1843.	1.6	210
24	Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1269-1282.	10.7	207
25	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. <i>Nature Genetics</i> , 2018, 50, 968-978.	21.4	184
26	Strain Rate Imaging Detects Early Cardiac Effects of Pegylated Liposomal Doxorubicin as Adjuvant Therapy in Elderly Patients with Breast Cancer. <i>Journal of the American Society of Echocardiography</i> , 2008, 21, 1283-1289.	2.8	165
27	The impact of frailty on postoperative outcomes in individuals aged 65 and over undergoing elective surgery for colorectal cancer: A systematic review. <i>Journal of Geriatric Oncology</i> , 2016, 7, 479-491.	1.0	164
28	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016, 6, 1052-1067.	9.4	157
29	Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). <i>Annals of Oncology</i> , 2015, 26, 873-879.	1.2	151
30	Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. <i>Annals of Oncology</i> , 2007, 18, 1314-1321.	1.2	132
31	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. <i>Nature Genetics</i> , 2016, 48, 374-386.	21.4	125
32	Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). <i>Annals of Oncology</i> , 2007, 18, 64-69.	1.2	121
33	Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 77, 221-240.	4.4	121
34	Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). <i>Lancet Oncology</i> , The, 2021, 22, e327-e340.	10.7	121
35	What Every Oncologist Should Know About Geriatric Assessment for Older Patients With Cancer: Young International Society of Geriatric Oncology Position Paper. <i>Journal of Oncology Practice</i> , 2018, 14, 85-94.	2.5	120
36	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	21.4	120

#	ARTICLE	IF	CITATIONS
37	Death Rattle. <i>Journal of Pain and Symptom Management</i> , 2002, 23, 310-317.	1.2	116
38	Pharmacology of Anticancer Drugs in the Elderly Population. <i>Clinical Pharmacokinetics</i> , 2003, 42, 1213-1242.	3.5	110
39	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. <i>Nature Communications</i> , 2014, 5, 4999.	12.8	105
40	The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients. <i>European Journal of Cancer</i> , 2015, 51, 2808-2819.	2.8	105
41	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv219.	6.3	99
42	Functional decline in older patients with cancer receiving chemotherapy: A multicenter prospective study. <i>Journal of Geriatric Oncology</i> , 2017, 8, 196-205.	1.0	99
43	Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. <i>Lancet Oncology</i> , The, 2018, 19, 323-336.	10.7	94
44	Does Estrogen Receptor-“Negative/Progesterone Receptor-“Positive Breast Carcinoma Exist?. <i>Journal of Clinical Oncology</i> , 2008, 26, 335-336.	1.6	91
45	Atropine, Hyoscine Butylbromide, or Scopolamine Are Equally Effective for the Treatment of Death Rattle in Terminal Care. <i>Journal of Pain and Symptom Management</i> , 2009, 38, 124-133.	1.2	90
46	Cancer and Aging: Two Tightly Interconnected Biological Processes. <i>Cancers</i> , 2021, 13, 1400.	3.7	83
47	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	4.5	82
48	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	9.4	79
49	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-“ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	12.8	78
50	Evaluating the physiological reserves of older patients with cancer: The value of potential biomarkers of aging?. <i>Journal of Geriatric Oncology</i> , 2014, 5, 204-218.	1.0	74
51	Relationship Between Age and Axillary Lymph Node Involvement in Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2931-2937.	1.6	72
52	Questionnaires and instruments for a multidimensional assessment of the older cancer patient: What clinicians need to know?. <i>European Journal of Cancer</i> , 2010, 46, 1019-1025.	2.8	72
53	The influence of clinical assessment (including age) and geriatric assessment on treatment decisions in older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2013, 4, 235-241.	1.0	72
54	Priorities for the global advancement of care for older adults with cancer: an update of the International Society of Geriatric Oncology Priorities Initiative. <i>Lancet Oncology</i> , The, 2021, 22, e29-e36.	10.7	71

#	ARTICLE	IF	CITATIONS
55	Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T&E) vs physician's choice in previously treated HER2-positive advanced breast cancer. <i>International Journal of Cancer</i> , 2016, 139, 2336-2342.	5.1	69
56	How to Implement a Geriatric Assessment in Your Clinical Practice. <i>Oncologist</i> , 2014, 19, 1056-1068.	3.7	68
57	Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). <i>Annals of Oncology</i> , 2015, 26, 1677-1684.	1.2	68
58	Geriatric assessment in the management of older patients with cancer – A systematic review (update). <i>Journal of Geriatric Oncology</i> , 2022, 13, 761-777.	1.0	67
59	Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis. <i>ESMO Open</i> , 2020, 5, e000947.	4.5	63
60	Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 67-76.	2.5	61
61	Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1190-1198.	1.0	60
62	Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). <i>Annals of Oncology</i> , 2013, 24, 1513-1525.	1.2	57
63	Taxanes in elderly breast cancer patients. <i>Cancer Treatment Reviews</i> , 2004, 30, 333-342.	7.7	56
64	Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. <i>Breast Cancer Research and Treatment</i> , 2005, 91, 81-87.	2.5	56
65	Value of geriatric screening and assessment in predicting postoperative complications in patients older than 70 years undergoing surgery for colorectal cancer. <i>Journal of Geriatric Oncology</i> , 2017, 8, 320-327.	1.0	54
66	Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium. <i>Annals of Oncology</i> , 2018, 29, 1987-1994.	1.2	52
67	Qualitative Assessment of the Progesterone Receptor and HER2 Improves the Nottingham Prognostic Index Up to 5 Years After Breast Cancer Diagnosis. <i>Journal of Clinical Oncology</i> , 2010, 28, 4129-4134.	1.6	51
68	Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force. <i>Cancer Treatment Reviews</i> , 2016, 43, 19-26.	7.7	51
69	Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial. <i>Clinical Cancer Research</i> , 2018, 24, 2312-2318.	7.0	51
70	Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. <i>European Journal of Cancer</i> , 2019, 118, 169-177.	2.8	51
71	Triple-negative breast cancer in the older population. <i>Annals of Oncology</i> , 2012, 23, vi52-vi55.	1.2	50
72	Circulating MicroRNAs as Easy-to-Measure Aging Biomarkers in Older Breast Cancer Patients: Correlation with Chronological Age but Not with Fitness/Frailty Status. <i>PLoS ONE</i> , 2014, 9, e110644.	2.5	49

#	ARTICLE	IF	CITATIONS
73	A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 109.	5.0	48
74	Triple negative breast cancer: Clinical characteristics in the different histological subtypes. <i>Breast</i> , 2013, 22, 761-766.	2.2	47
75	Implementation of geriatric assessment-based recommendations in older patients with cancer: A multicentre prospective study. <i>Journal of Geriatric Oncology</i> , 2015, 6, 401-410.	1.0	47
76	Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. <i>Annals of Oncology</i> , 2012, 23, 2578-2584.	1.2	46
77	Characteristics and effectiveness of complex nursing interventions aimed at reducing symptom burden in adult patients treated with chemotherapy: A systematic review of randomized controlled trials. <i>International Journal of Nursing Studies</i> , 2014, 51, 495-510.	5.6	46
78	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. <i>Nature Communications</i> , 2020, 11, 6335.	12.8	46
79	The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients. <i>British Journal of Cancer</i> , 2016, 115, 1471-1478.	6.4	45
80	Body mass index and breast cancer survival: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2017, 46, 1814-1822.	1.9	45
81	Biological ageing and frailty markers in breast cancer patients. <i>Aging</i> , 2015, 7, 319-333.	3.1	45
82	Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 463-469.	2.5	44
83	Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. <i>Breast</i> , 2015, 24, 182-190.	2.2	44
84	Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. <i>Breast Cancer Research</i> , 2017, 19, 119.	5.0	43
85	Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. <i>Acta Clinica Belgica</i> , 2018, 73, 100-109.	1.2	42
86	Main priorities for the development of geriatric oncology: A worldwide expert perspective. <i>Journal of Geriatric Oncology</i> , 2011, 2, 270-273.	1.0	41
87	Dealing with chemotherapy-related symptoms at home: a qualitative study in adult patients with cancer. <i>European Journal of Cancer Care</i> , 2016, 25, 79-92.	1.5	41
88	HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology. <i>Journal of Geriatric Oncology</i> , 2019, 10, 1003-1013.	1.0	40
89	Geriatric Assessment and Functional Decline in Older Patients with Lung Cancer. <i>Lung</i> , 2017, 195, 619-626.	3.3	39
90	Postoperative complications in individuals aged 70 and over undergoing elective surgery for colorectal cancer. <i>Colorectal Disease</i> , 2017, 19, O329-O338.	1.4	39

#	ARTICLE	IF	CITATIONS
91	Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. <i>Supportive Care in Cancer</i> , 2018, 26, 869-878.	2.2	39
92	The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters. <i>Oncotarget</i> , 2016, 7, 29977-29988.	1.8	39
93	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. <i>Human Molecular Genetics</i> , 2015, 24, 285-298.	2.9	38
94	Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. <i>JCO Global Oncology</i> , 2021, 7, 162-172.	1.8	38
95	Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. <i>Annals of Oncology</i> , 2022, 33, 769-785.	1.2	37
96	Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study. <i>Anti-Cancer Drugs</i> , 2004, 15, 341-346.	1.4	36
97	Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. <i>European Journal of Cancer</i> , 2020, 125, 69-82.	2.8	36
98	Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data. <i>Annals of Oncology</i> , 2013, 24, 350-355.	1.2	35
99	Breast cancer phenotype, nodal status and palpability may be useful in the detection of overdiagnosed screening-detected breast cancers. <i>Annals of Oncology</i> , 2013, 24, 1847-1852.	1.2	34
100	The role of vitamin D in breast cancer risk and progression. <i>Endocrine-Related Cancer</i> , 2022, 29, R33-R55.	3.1	34
101	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. <i>Human Molecular Genetics</i> , 2016, 25, 3863-3876.	2.9	33
102	Computerised scoring protocol for identification and quantification of different immune cell populations in breast tumour regions by the use of QuPath software. <i>Histopathology</i> , 2020, 77, 79-91.	2.9	33
103	Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty. <i>Breast Cancer Research</i> , 2017, 19, 20.	5.0	32
104	Behavior of metastatic breast cancer according to subtype. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 115-125.	2.5	32
105	Effects of a mindfulness-based intervention on cancer-related cognitive impairment: Results of a randomized controlled functional magnetic resonance imaging pilot study. <i>Cancer</i> , 2020, 126, 4246-4255.	4.1	32
106	The added value of geriatric screening and assessment for predicting overall survival in older patients with cancer. <i>Cancer</i> , 2018, 124, 3753-3763.	4.1	31
107	Anticancer drugs are not well tolerated in all older patients with cancer. <i>The Lancet Healthy Longevity</i> , 2020, 1, e43-e47.	4.6	31
108	Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 146-153.	6.3	31

#	ARTICLE	IF	CITATIONS
109	Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape. <i>ESMO Open</i> , 2021, 6, 100204.	4.5	30
110	Oncological care organisation during COVID-19 outbreak. <i>ESMO Open</i> , 2020, 5, e000853.	4.5	29
111	Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 103-112.	2.5	26
112	Lobular and non-lobular breast cancers differ regarding axillary lymph node metastasis: a cross-sectional study on 4,292 consecutive patients. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 429-435.	2.5	26
113	Multicenter implementation of geriatric assessment in Belgian patients with cancer: A survey on treating physicians' general experiences and expectations. <i>Journal of Geriatric Oncology</i> , 2014, 5, 431-438.	1.0	26
114	A Belgian survey on geriatric assessment in oncology focusing on large-scale implementation and related barriers and facilitators. <i>Journal of Nutrition, Health and Aging</i> , 2016, 20, 60-70.	3.3	26
115	Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer. <i>Annals of Oncology</i> , 2011, 22, 588-594.	1.2	25
116	Comprehensive geriatric assessment (CGA) in older oncological patients: Why and how?. <i>Journal of Geriatric Oncology</i> , 2012, 3, 174-176.	1.0	25
117	Age-dependent brain volume and neuropsychological changes after chemotherapy in breast cancer patients. <i>Human Brain Mapping</i> , 2019, 40, 4994-5010.	3.6	25
118	Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 557-570.	2.5	23
119	Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. <i>Oncologist</i> , 2019, 24, 165-171.	3.7	23
120	Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery. <i>Quality of Life Research</i> , 2019, 28, 663-676.	3.1	23
121	Relevance of Geriatric Assessment in Older Patients With Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, e221-e229.	2.3	22
122	The footprint of the ageing stroma in older patients with breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 78.	5.0	22
123	Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 699-708.	2.5	22
124	Taxanes and anthracyclines in early breast cancer: which first?. <i>Lancet Oncology</i> , The, 2010, 11, 219-220.	10.7	20
125	Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors. <i>BMC Cancer</i> , 2014, 14, 201.	2.6	20
126	Health related quality of life in older patients with solid tumors and prognostic factors for decline. <i>Journal of Geriatric Oncology</i> , 2019, 10, 895-903.	1.0	20

#	ARTICLE	IF	CITATIONS
127	Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in <i>BRCA1/2</i> : A Review of Secondary Prevention Guidelines. <i>Journal of Oncology</i> , 2020, 2020, 1-13.	1.3	20
128	Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 417-428.	2.5	20
129	Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 127-133.	2.5	19
130	Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial. <i>Annals of Oncology</i> , 2022, 33, 299-309.	1.2	19
131	Intra-hepatic Mitomycin C bolus infusion in the treatment of extensive liver metastases of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 135-142.	2.5	18
132	A nursing intervention aimed at reducing symptom burden during chemotherapy (CHEMO-SUPPORT): A mixed-methods study of the patient experience. <i>European Journal of Oncology Nursing</i> , 2018, 34, 35-41.	2.1	18
133	A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in medically fit elderly breast cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 67, 133-138.	4.4	17
134	Implementation of uHear, an iOS-based application to screen for hearing loss - in older patients with cancer undergoing a comprehensive geriatric assessment. <i>Journal of Geriatric Oncology</i> , 2016, 7, 126-133.	1.0	17
135	A Systematic Review of Estimating Breast Cancer Recurrence at the Population Level With Administrative Data. <i>Journal of the National Cancer Institute</i> , 2020, 112, 979-988.	6.3	17
136	Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study. <i>Acta Oncologica</i> , 2022, 61, 22-29.	1.8	17
137	A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis. <i>Annals of Oncology</i> , 2010, 21, 419-423.	1.2	16
138	Omitting radiation therapy in women with triple-negative breast cancer leads to worse breast cancer-specific survival. <i>Breast</i> , 2017, 32, 18-25.	2.2	16
139	Use of a symptom diary during chemotherapy: A mixed-methods evaluation of the patient perspective. <i>European Journal of Oncology Nursing</i> , 2017, 31, 37-45.	2.1	16
140	The effect of adjuvant chemotherapy on symptom burden and quality of life over time; a preliminary prospective observational study using individual data of patients aged ≥ 70 with early stage invasive breast cancer. <i>Journal of Geriatric Oncology</i> , 2018, 9, 152-162.	1.0	16
141	Underrepresentation of vulnerable older patients with cancer in phase II and III oncology registration trials: A case-control study. <i>Journal of Geriatric Oncology</i> , 2020, 11, 320-326.	1.0	16
142	Melphalan availability in hypoxia-inducible factor-1 ^{+/+} and factor-1 ^{-/-} tumors is independent of tumor vessel density and correlates with melphalan erythrocyte transport. <i>International Journal of Cancer</i> , 2002, 99, 514-519.	5.1	15
143	Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 609.	7.1	15
144	The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. <i>Oncotarget</i> , 2015, 6, 7390-7407.	1.8	15

#	ARTICLE	IF	CITATIONS
145	Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens. <i>European Journal of Cancer</i> , 2014, 50, 2925-2931.	2.8	14
146	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. <i>Breast Cancer Research</i> , 2014, 16, R51.	5.0	14
147	Integrating geriatric assessment in the first line chemotherapy treatment in older patients with metastatic colorectal cancer: Results of a prospective observational cohort study (AVAPLUS). <i>Journal of Geriatric Oncology</i> , 2018, 9, 93-101.	1.0	14
148	Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breast. <i>European Journal of Surgical Oncology</i> , 2019, 45, 550-559.	1.0	14
149	SIOG guidelines- essential for good clinical practice in geriatric oncology. <i>Journal of Geriatric Oncology</i> , 2019, 10, 196-198.	1.0	14
150	Unplanned hospitalizations in older patients with cancer: Occurrence and predictive factors. <i>Journal of Geriatric Oncology</i> , 2021, 12, 368-374.	1.0	14
151	Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5818-5827.	7.0	14
152	Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 183-194.	2.5	14
153	Adjuvant chemotherapy in elderly patients with breast cancer: where are we?. <i>Current Opinion in Oncology</i> , 2005, 17, 566-572.	2.4	13
154	Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients. <i>Drugs and Aging</i> , 2015, 32, 821-834.	2.7	12
155	Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy. <i>BMC Cancer</i> , 2018, 18, 1014.	2.6	12
156	Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 131-141.	2.5	12
157	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421.	3.7	12
158	Immuno affinity purification combined with mass spectrometry detection for the monitoring of VEGF isoforms in patient tumor tissue. <i>Journal of Separation Science</i> , 2003, 26, 619-623.	2.5	11
159	The prognostic value of 3 commonly measured blood parameters and geriatric assessment to predict overall survival in addition to clinical information in older patients with cancer. <i>Cancer</i> , 2018, 124, 3764-3775.	4.1	11
160	The SIOG COVID-19 working group recommendations on the rollout of COVID-19 vaccines among older adults with cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 848-850.	1.0	11
161	Challenges in treating older cancer patients: breast cancer. <i>Annals of Oncology</i> , 2008, 19, vii99-vii103.	1.2	10
162	Prognostic implications of lobular breast cancer histology: New insights from a single hospital cross-sectional study and SEER data. <i>Breast</i> , 2014, 23, 371-377.	2.2	10

#	ARTICLE	IF	CITATIONS
163	The influence of coping strategies on subsequent well-being in older patients with cancer: A comparison with 2 control groups. <i>Psycho-Oncology</i> , 2018, 27, 864-870.	2.3	10
164	Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO). <i>Breast Cancer Research and Treatment</i> , 2019, 176, 607-615.	2.5	10
165	Efficacy and safety of first-line veliparib and carboplatin+paclitaxel in patients with HER2+ advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial. <i>European Journal of Cancer</i> , 2021, 154, 35-45.	2.8	10
166	Systematic development of CHEMO-SUPPORT, a nursing intervention to support adult patients with cancer in dealing with chemotherapy-related symptoms at home. <i>BMC Nursing</i> , 2018, 17, 28.	2.5	9
167	Targeted therapy for breast cancer in older patients. <i>Journal of Geriatric Oncology</i> , 2020, 11, 380-388.	1.0	9
168	Breast Cancer Detection and Treatment Monitoring Using a Noninvasive Prenatal Testing Platform: Utility in Pregnant and Nonpregnant Populations. <i>Clinical Chemistry</i> , 2020, 66, 1414-1423.	3.2	9
169	Assessment of stromal tumor infiltrating lymphocytes and immunohistochemical features in invasive micropapillary breast carcinoma with long-term outcomes. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 985-998.	2.5	9
170	Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover). <i>Clinical Cancer Research</i> , 2021, 27, 4983-4993.	7.0	9
171	The EORTC Cancer in the Elderly Task Force, a Protostar for EORTC's future. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 34-38.	2.2	8
172	Circulating CCL5 Levels in Patients with Breast Cancer: Is There a Correlation with Lymph Node Metastasis?. <i>ISRN Immunology</i> , 2013, 2013, 1-5.	0.7	8
173	Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2019, 19, 47-57.	2.4	8
174	Real-time symptom management in the context of a remote symptom-monitoring system: prospective process evaluation and cross-sectional survey to explore clinical relevance. <i>Supportive Care in Cancer</i> , 2021, 29, 3401-3408.	2.2	8
175	Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3. <i>ESMO Open</i> , 2021, 6, 100203.	4.5	8
176	Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 189-196.	2.5	7
177	Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Portal Hypertension-Induced Refractory Ascites Due to Metastatic Carcinomatous Liver Disease. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1713-1716.	0.5	7
178	Intra-arterial Mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 597-605.	2.5	7
179	The prognostic value of patient-reported Health-Related Quality of Life and Geriatric Assessment in predicting early death in 6769 older (≥70 years) patients with different cancer tumors. <i>Journal of Geriatric Oncology</i> , 2020, 11, 926-936.	1.0	7
180	Identifying frailty in clinically fit patients diagnosed with hematological malignancies using a simple clinico-biological screening tool: The HEMA-4 study. <i>Journal of Geriatric Oncology</i> , 2021, 12, 902-908.	1.0	7

#	ARTICLE	IF	CITATIONS
181	Targeted Therapies in Older Adults With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2021, 39, 2128-2137.	1.6	7
182	POLRMT as a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients. <i>Pharmaceutics</i> , 2021, 13, 1942.	4.5	7
183	Preventing taxane-related peripheral neuropathy, pain and nail toxicity: a prospective self-controlled trial comparing hilotherapy with frozen gloves in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 293-301.	2.5	7
184	A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients. <i>BMC Cancer</i> , 2015, 15, 978.	2.6	6
185	Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 603-607.	2.5	6
186	Breast cancer subtype and survival by parity and time since last birth. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 481-487.	2.5	6
187	UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer. <i>European Journal of Cancer</i> , 2018, 103, 184-194.	2.8	6
188	Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and Blueprint® Kit at University Hospitals Leuven and Curie Institute Paris. <i>Translational Oncology</i> , 2019, 12, 1557-1565.	3.7	6
189	The added value of geriatric assessment in evaluating a patient's Health-Related Quality of Life: A study in a 70-year-old early-stage invasive breast cancer patients. <i>European Journal of Cancer Care</i> , 2020, 29, e13278.	1.5	6
190	Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets. <i>Clinical Chemistry</i> , 2022, 68, 1164-1176.	3.2	6
191	Low levels of intra-tumoural T cells in breast cancer identify clinically frail patients with shorter disease-specific survival. <i>Journal of Geriatric Oncology</i> , 2018, 9, 606-612.	1.0	5
192	Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies. <i>Acta Clinica Belgica</i> , 2019, 74, 169-179.	1.2	5
193	Risk-reducing mastectomy in BRCA carriers: survival is not the issue. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 251-252.	2.5	5
194	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. <i>British Journal of Cancer</i> , 2021, 124, 842-854.	6.4	5
195	Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2~ early breast cancer. <i>Modern Pathology</i> , 2021, 34, 1297-1309.	5.5	5
196	Cause of death for patients with breast cancer: discordance between death certificates and medical files, and impact on survival estimates. <i>Archives of Public Health</i> , 2021, 79, 111.	2.4	5
197	Sequential intra-arterial infusion of 90Y-resin microspheres and mitomycin C in chemo refractory liver metastatic breast cancer patients: a single centre pilot study. <i>Radiology and Oncology</i> , 2020, 54, 33-39.	1.7	5
198	Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression. <i>Breast</i> , 2022, 64, 100-111.	2.2	5

#	ARTICLE	IF	CITATIONS
199	Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer. <i>Clinical Drug Investigation</i> , 2018, 38, 1071-1075.	2.2	4
200	A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 121-133.	2.5	4
201	Cancer events in Belgian nursing home residents: An EORTC prospective cohort study. <i>Journal of Geriatric Oncology</i> , 2019, 10, 805-810.	1.0	4
202	Scalp cooling in breast cancer patients treated with docetaxel+cyclophosphamide: patient- and nurse-reported results. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 715-722.	2.5	4
203	Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global survey. <i>ESMO Open</i> , 2021, 6, 100219.	4.5	4
204	Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial. <i>Journal of Geriatric Oncology</i> , 2022, 13, 582-593.	1.0	4
205	Elevated CA 15.3 in Newly Diagnosed Breast Cancer: A Retrospective Study. <i>Clinical Breast Cancer</i> , 2022, 22, 579-587.	2.4	4
206	Withdrawal of hormone replacement therapy might affect multigene signature results in early luminal breast cancer. <i>Annals of Oncology</i> , 2015, 26, 437-438.	1.2	3
207	Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 55-63.	2.5	3
208	Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study. <i>ESMO Open</i> , 2021, 6, 100207.	4.5	3
209	The Combination of the CDK4/6 Inhibitor, Palbociclib, With the Vitamin D3 Analog, Inecalcitol, Has Potent In Vitro and In Vivo Anticancer Effects in Hormone-Sensitive Breast Cancer, But Has a More Limited Effect in Triple-Negative Breast Cancer. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	3
210	Different adjuvant chemotherapy regimens in older breast cancer patients?. <i>Annals of Oncology</i> , 2015, 26, 613-615.	1.2	2
211	A Case of Severe Acute Cardiac Failure on Sunitinib After Left-Sided Thoracal Radiation Therapy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e155-e158.	1.9	2
212	The utilization of formal and informal home care by older patients with cancer: a Belgian cohort study with two control groups. <i>BMC Health Services Research</i> , 2017, 17, 644.	2.2	2
213	Retrospective Analysis of the Clinical Presentation, Treatment and Outcome of Angiosarcoma in a Sarcoma Referral Center. <i>Oncology Research and Treatment</i> , 2021, 44, 322-332.	1.2	2
214	Blood Immunosenescence Signatures Reflecting Age, Frailty and Tumor Immune Infiltrate in Patients with Early Luminal Breast Cancer. <i>Cancers</i> , 2021, 13, 2185.	3.7	2
215	Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 128.	5.2	2
216	Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 357-372.	2.5	2

#	ARTICLE	IF	CITATIONS
217	948â€¦Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC. , 2021, 9, A997-A997.		2
218	Updated SIOG COVID-19 working group recommendations on COVID-19 vaccination among older adults with cancer. Journal of Geriatric Oncology, 2022, , .	1.0	2
219	Adverse events with everolimus in BOLERO-2. Annals of Oncology, 2014, 25, 1861.	1.2	1
220	ADJUVANT CHEMOTHERAPY IN OLDER BREAST CANCER PATIENTS: HOW TO DECIDE. Journal of Geriatric Oncology, 2014, 5, S3.	1.0	1
221	Bone metastases and age are associated with earlier dose reductions in metastatic clear-cell renal cell carcinoma patients treated with angiogenesis inhibitors. Acta Clinica Belgica, 2019, 74, 414-423.	1.2	1
222	How to use dialysis wisely in cancer patients?. Journal of Onco-Nephrology, 2021, 5, 79-86.	0.6	1
223	Immune-related adverse events after a single dose of pembrolizumab. European Journal of Cancer, 2021, 148, 92-94.	2.8	1
224	Intra-Arterial Therapies for Liver Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. CardioVascular and Interventional Radiology, 2021, 44, 1868-1882.	2.0	1
225	Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1041-1048.	2.5	1
226	Reply to T. To et al.. Journal of Geriatric Oncology, 2014, 5, 221-222.	1.0	0
227	Solitary pituitary metastasis from HER2-positive breast cancer treated with stereotactic radiotherapy â€œ a case report. Current Problems in Cancer Case Reports, 2021, 4, 100081.	0.1	0
228	Administration of 24-hour intravenous infusions of trabectedin every 3 weeks in ambulatory patients with mesenchymal tumors via disposable elastomeric pumps. Journal of Clinical Oncology, 2009, 27, e13530-e13530.	1.6	0
229	The influence of age plus standard clinical approach with or without comprehensive geriatric assessment (CGA) on treatment decisions in older cancer patients: Final results.. Journal of Clinical Oncology, 2012, 30, 9035-9035.	1.6	0
230	The impact of genetic variability on severe toxicity of (neo-) adjuvant chemotherapy in breast cancer patients receiving 5-fluorouracil, epirubicin, and cyclofosfamide (FEC).. Journal of Clinical Oncology, 2012, 30, 1020-1020.	1.6	0
231	The impact of patient-related factors on the occurrence of febrile neutropenia in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin, and cyclofosfamide (FEC) x6 or FEC x3 followed by docetaxel (D) x3.. Journal of Clinical Oncology, 2013, 31, 1078-1078.	1.6	0
232	Prediction of Poor Outcome in Older Patients Receiving Chemotherapy for Malignant Lymphoma: A New Frailty Scoring. Blood, 2016, 128, 2353-2353.	1.4	0
233	Cognitive Impairment, Hypoalbuminemia, High CRP Level and Past History of Gastro-Intestinal Ulcer: 4 Markers of Frailty Which Identify Older Patients with Malignant Hemopathies Who Shouldn't Benefit from Chemotherapy. Blood, 2018, 132, 4756-4756.	1.4	0
234	Medical Management of Advanced Disease. , 2019, , 219-228.		0

#	ARTICLE	IF	CITATIONS
235	Clinical Trial Design for Older Cancer Patients. , 2020, , 1-7.		0
236	Clinical Trial Design for Older Cancer Patients. , 2021, , 1042-1048.		0
237	Abstract P2-08-23: Early intratumoral changes after a single dose of anti-PD-1 treatment in patients with early breast cancer (BC). Cancer Research, 2022, 82, P2-08-23-P2-08-23.	0.9	0